Brainstorm Cell Therapeutics Misses Q1 EPS by 2c

  • Investing.com
Brainstorm Cell Therapeutics Misses Q1 EPS by 2c

Brainstorm Cell Therapeutics (NASDAQ: BCLI ) reported Q1 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13).

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100